Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 2/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.57 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | ACP1 | P24666 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743007 | 0.86 | KMT2A (0.72) | SCDDYRK1AKMT2AMMP13ACP1 | |
| SCHEMBL31349444 | 0.82 | KMT2A (0.68) | DYRK1AKMT2AACP1NPC1RAB9A | |
| SCHEMBL31349449 | 0.82 | KMT2A (0.68) | DYRK1AKMT2AACP1NPC1RAB9A | |
| SCHEMBL594516 | 0.82 | SCD (0.69) | SCDDYRK1AKMT2AMMP13NPC1 | |
| SCHEMBL12095405 | 0.79 | NPC1 (0.78) | SCDDYRK1AKMT2AMMP13ACP1 | |
| SCHEMBL14375443 | 0.77 | SCD (0.69) | SCDDYRK1AKMT2AMMP13NPC1 | |
| SCHEMBL16747337 | 0.76 | DYRK1A (0.77) | SCDDYRK1AKMT2AACP1NPC1 | |
| SCHEMBL10308069 | 0.75 | ABCG2 (0.54) | KMT2ANPC1RAB9AMAPTGAA | |
| SCHEMBL23529343 | 0.75 | RAB9A (0.68) | DYRK1ACSNK1DMMP13ACP1NPC1 | |
| SCHEMBL3791611 | 0.75 | DYRK1A (0.78) | DYRK1ACSNK1DACP1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287098-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2021-04-22 | — | — | US | disclosed |
| WO-2019217509-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | VHL, TP53, NUDT1 | SCD 4478/4885DYRK1A 4664/4885CSNK1D 3599/4885 |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | VHL, TP53, NUDT1 | SCD 4591/4885DYRK1A 4618/4885CSNK1D 3509/4885 |
| US-20240287098-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | VHL, TP53, NUDT1 | SCD 4478/4885DYRK1A 4664/4885CSNK1D 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.